Izvi zvakabudiswa zvakaratidza Dupixent, kana yakawedzerwa kuhutano hwehutano, yakaderedza zvakanyanya kurwiswa kweasma uye, mukati memavhiki maviri, yakakurumidza kuvandudza kushanda kwemapapu muhuwandu hwevanhu vane eosinophilic phenotype, sezvinoratidzwa nepamusoro-soro eosinophils yeropa, imwe mhando yeropa chena, uye/kana ine yakakwira fractional exhaled nitric oxide (FeNO), mugwagwa wemhepo biomarker yekuzvimba inoita basa guru muasthma.
"Kudhindwa kweizvi Phase 3 mhedzisiro yeDupixent muNew England Journal of Medicine inosimbisa kukosha kwavo uye inogona kuve yakakosha yekiriniki yevana vadiki vane isingadzorerwe pakati-kusvika-yakanyanya asima," akadaro Leonard B. Bacharier, MD, Purofesa wePediatrics uye Director. weCentre for Pediatric Asthma Research, Monroe Carell Jr. Children's Hospital paVanderbilt University Medical Center muNashville, Tennessee, uye mukuru anoongorora nyaya yacho. "Idzi data dzinowedzerawo manzwisisiro edu ekugadzirisa kuzvimba kwerudzi rwechipiri, chirongwa chebiological chinokonzera zviitiko zvakawanda zveasima muhuduku, zvinogona kuvandudza zviratidzo nemhedzisiro kuvana vanorwara nechirwere ichi chisingaperi."
Asthma ndechimwe chezvirwere zvinowanzoitika muvana. Vanosvika 75,000 vana vane makore matanhatu kusvika gumi nerimwe vanogara neiyo isingadzoreki ine mwero-kusvika-yakanyanya fomu yechirwere muUS, uye zvimwe zvakawanda pasi rose. Pasinei nekurapwa neazvino chiyero-yekutarisira inhaled corticosteroids uye bronchodilators, vana ava vanogona kuramba vachiona zviratidzo zvakakomba senge kukosora, kufema uye kunetseka kufema. Ivo zvakare vangangoda akawanda makosi e systemic corticosteroids anogona kutakura akakosha ekuchengetedza njodzi.
Migumisiro yekuchengetedzwa kubva mukuedzwa yaiwanzoenderana neyakazivikanwa kuchengetedzwa kweDupixent muvarwere vane makore gumi nemaviri uye kupfuura vane isingadzoreki pakati-kusvika-yakaoma asthma, pamwe nekuwedzera kwezvirwere zvehelminth zvakataurwa mu12% yevarwere veDupixent uye 2.2% yevarwere ve placebo. Izvo zviyero zvezviitiko zvakashata zvaive 0.7% yeDupixent uye 83% ye placebo. Zviitiko zvakaipisisa zvaiwanzoonekwa neDupixent zvichienzaniswa ne placebo zvaive jekiseni site reactions (80% Dupixent, 18% placebo), utachiona hwepamusoro hwekufema hutachiwana (13% Dupixent, 12% placebo) uye eosinophilia (10% Dupixent, 6% placebo).
Dupixent, iyo yakagadzirwa uchishandisa Regeneron's proprietary VelocImmune® tekinoroji, ndeye munhu akazara monoclonal antibody inodzivirira kusaina kweiyo interleukin-4 (IL-4) uye interleukin-13 (IL-13) nzira uye haisi immunosuppressant. IL-4 uye IL-13 ndiwo akakosha uye epakati madhiraivha erudzi rwechipiri kuzvimba kunoita basa rakakura muatopic dermatitis, asthma uye chisingaperi rhinosinusitis ine nasal polyposis (CRSwNP).
Mhedzisiro yemuyedzo weChikamu 3 iyi yakaverengerwawo muEuropean regulatory fileing, uye sarudzo kubva kuEuropean Medicines Agency muvana vane isingadzoreki yakaoma asima inotarisirwa muQ1 2022.